Patents by Inventor Sofie Struyf

Sofie Struyf has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Novel Inhibitors of Angiogenesis
    Publication number: 20090011981
    Abstract: The present invention provides novel inhibitors of angiogenesis. The invention relates to PF4var1 and fragments and modifications thereof with anti-angiogenic activity. Therefore, the present invention relates to the use of said proteins and peptides as a medicine, more in particular for the treatment or prevention of angiogenesis or for the manufacture of a medicament for the prevention or treatment of angiogenic diseases. The invention also provides pharmaceutical compositions comprising said proteins and peptides and method of preventing or treating angiogenic disorders.
    Type: Application
    Filed: August 15, 2005
    Publication date: January 8, 2009
    Applicants: K.U. LEUVEN RESEARCH & DEVELOPMENT, THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Jozef Van Damme, Paul Proost, Sofie Struyf, Robert Strieter, Marie D. Burdick
  • Amino-terminally truncated MCP-2 as chemokine antagonists
    Patent number: 7338653
    Abstract: The present invention relates to amino-terminally truncated MCP-2, lacking NH2-terminal amino acids corresponding to amino acid residues 1, 1-2, 1-3, 1-4 or 1-5 of the naturally-occurring MCP-2 and having chemokine antagonistic activity, as well as cDNA sequences encoding them, their use in therapy and/or in diagnosis of the diseases, in which an antagonistic activity of the chemokine effects is required, and pharmaceutical compositions comprising them.
    Type: Grant
    Filed: May 6, 2005
    Date of Patent: March 4, 2008
    Assignee: Laboratoires Serono SA
    Inventors: Paul Proost, Sofie Struyf, Jo Van Damme
  • Use of amino-terminally truncated RANTES to inhibit HIV viral replication
    Patent number: 7326411
    Abstract: The present invention relates to amino-terminally truncated RANTES, lacking NH2-terminal amino acids corresponding to amino acid residues 1, 1-2, 1-3 or 1-4 of the naturally-occurring RANTES (SEQ ID NO:2) and having chemokine antagonistic activity, as well as cDNA sequences encoding them, their use in therapy and/or in diagnosis of the diseases, in which an antagonistic activity of the chemokine effects is required, and pharmaceutical compositions comprising them.
    Type: Grant
    Filed: March 7, 2005
    Date of Patent: February 5, 2008
    Assignee: Laboratoires Serono SA
    Inventors: Paul Proost, Sofie Struyf, Jo Van Damme
  • Amino-terminally truncated RANTES as chemokine antagonists
    Patent number: 6977071
    Abstract: The present invention relates to amino-terminally truncated RANTES, lacking NH2-terminal amino acids corresponding to amino acid residues 1, 1-2, 1-3 or 1-4 of the naturally-occurring RANTES and having chemokine antagonistic activity, as well as cDNA sequences encoding them, their use in therapy and/or in diagnosis of the diseases, in which an antagonistic activity of the chemokine effects is required, and pharmaceutical compositions comprising them.
    Type: Grant
    Filed: March 28, 2000
    Date of Patent: December 20, 2005
    Assignee: Applied Research Systems ARS Holding NV
    Inventors: Paul Proost, Sofie Struyf, Jo Van Damme
  • Amino-terminally truncated rantes as chemokine antagonists
    Publication number: 20050220790
    Abstract: The present invention relates to amino-terminally truncated RANTES, lacking NH2-terminal amino acids corresponding to amino acid residues 1, 1-2, 1-3 or 1-4 of the naturally-occurring RANTES (SEQ ID NO:2) and having chemokine antagonistic activity, as well as cDNA sequences encoding them, their use in therapy and/or in diagnosis of the diseases, in which an antagonistic activity of the chemokine effects is required, and pharmaceutical compositions comprising them.
    Type: Application
    Filed: May 18, 2005
    Publication date: October 6, 2005
    Applicant: Applied Research Systems ARS Holding NV
    Inventors: Paul Proost, Sofie Struyf, Jo Van Damme
  • Amino-terminally truncated MCP-2 as chemokine antagonists
    Publication number: 20050201977
    Abstract: The present invention relates to amino-terminally truncated MCP-2, lacking NH2-terminal amino acids corresponding to amino acid residues 1, 1-2, 1-3, 1-4 or 1-5 of the naturally-occurring MCP-2 and having chemokine antagonistic activity, as well as cDNA sequences encoding them, their use in therapy and/or in diagnosis of the diseases, in which an antagonistic activity of the chemokine effects is required, and pharmaceutical compositions comprising them.
    Type: Application
    Filed: May 6, 2005
    Publication date: September 15, 2005
    Applicant: APPLIED RESEARCH SYSTEMS ARS HOLDING N.V
    Inventors: Paul Proost, Sofie Struyf, Jo Van Damme
  • Amino-terminally truncated rantes as chemokine antagonists
    Publication number: 20050164936
    Abstract: The present invention relates to amino-terminally truncated RANTES, lacking NH2-terminal amino acids corresponding to amino acid residues 1, 1-2, 1-3 or 1-4 of the naturally-occurring RANTES (SEQ ID NO:2) and having chemokine antagonistic activity, as well as cDNA sequences encoding them, their use in therapy and/or in diagnosis of the diseases, in which an antagonistic activity of the chemokine effects is required, and pharmaceutical compositions comprising them.
    Type: Application
    Filed: March 7, 2005
    Publication date: July 28, 2005
    Applicant: Applied Research Systems ARS Holding NV
    Inventors: Paul Proost, Sofie Struyf, Jo Van Damme
  • Amino-terminally truncated MCP-2 as chemokine antagonists
    Patent number: 6905676
    Abstract: The present invention relates to amino-terminally truncated MCP-2, lacking NH2-terminal amino acids corresponding to amino acid residues 1, 1-2, 1-3, 1-4 or 1-5 of the naturally-occurring MCP-2 and having chemokine antagonistic activity, as well as cDNA sequences encoding them, their use in therapy and/or in diagnosis of the diseases, in which an antagonistic activity of the chemokine effects is required, and pharmaceutical compositions comprising them.
    Type: Grant
    Filed: March 28, 2000
    Date of Patent: June 14, 2005
    Assignee: Applied Research Systems ARS Holding N.V.
    Inventors: Paul Proost, Sofie Struyf, Jo Van Damme
  • Amino-terminally truncated MCP-2 as chemokine antagonists
    Publication number: 20030124677
    Abstract: The present invention relates to amino-terminally truncated MCP-2, lacking NH2-terminal amino acids corresponding to amino acid residues 1, 1-2, 1-3, 1-4 or 1-5 of the naturally-occurring MCP-2 and having chemokine antagonistic activity, as well as cDNA sequences encoding them, their use in therapy and/or in diagnosis of the diseases, in which an antagonistic activity of the chemokine effects is required, and pharmaceutical compositions comprising them.
    Type: Application
    Filed: March 28, 2000
    Publication date: July 3, 2003
    Inventors: Paul Proost, Sofie Struyf, Jo Van Damme
  • Amino-terminally truncated rantes as chemokine antagonists
    Publication number: 20030119148
    Abstract: The present invention relates to amino-terminally truncated RANTES, lacking NH2-terminal amino acids corresponding to amino acid residues 1, 1-2, 1-3 or 1-4 of the naturally-occurring RANTES and having chemokine antagonistic activity, as well as cDNA sequences encoding them, their use in therapy and/or in diagnosis of the diseases, in which an antagonistic activity of the chemokine effects is required, and pharmaceutical compositions comprising them.
    Type: Application
    Filed: March 28, 2000
    Publication date: June 26, 2003
    Inventors: Paul Proost, Sofie Struyf, Jo Van Damme